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Abstract
The P23H mutation in the rhodopsin gene causes rhodopsin misfolding, altered trafficking and formation of insoluble
aggregates leading to photoreceptor degeneration and autosomal dominant retinitis pigmentosa (RP). There are no
effective therapies to treat this condition. Compounds that enhance dissociation of protein aggregates may be of value in
developing new treatments for such diseases. Anti-protein aggregating activity of curcumin has been reported earlier. In
this study we present that treatment of COS-7 cells expressing mutant rhodopsin with curcumin results in dissociation of
mutant protein aggregates and decreases endoplasmic reticulum stress. Furthermore we demonstrate that administration
of curcumin to P23H-rhodopsin transgenic rats improves retinal morphology, physiology, gene expression and localization
of rhodopsin. Our findings indicate that supplementation of curcumin improves retinal structure and function in P23H-
rhodopsin transgenic rats. This data also suggest that curcumin may serve as a potential therapeutic agent in treating RP
due to the P23H rhodopsin mutation and perhaps other degenerative diseases caused by protein trafficking defects.
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Introduction
Retinal degenerations are a group of heterogeneous diseases of
the retina, which result in irreversible blindness. Age related
macular degeneration (AMD) and retinitis pigmentosa (RP) are the
most common degenerative diseases of the retina. AMD is
characterized by loss of central vision whereas RP is typically
characterized as a rod-cone dystrophy in which the genetic defects
cause cell death of rod and cone photoreceptors, predominantly
the degeneration of rod photoreceptors [1,2,3]. RP affects around
1.5 million people worldwide. This disease can be inherited in
autosomal dominant, autosomal recessive, X-linked or syndromic
forms [4]. Mutations in more than 40 genes are associated with RP
[5 RetNet web site-: Available: http://www.sph.uth.tmc.edu/
Retnet/disease.htm Accessed 2011 May 25]. Mutations in
rhodopsin are the most common cause of RP [6,7]. Rhodopsin
is a G-protein coupled receptor and the most abundant protein in
rod photoreceptor cells. It consists of the polypeptide opsin and a
single covalently bound molecule of the chromophore, 11-cis
retinal. Many mutations have been found in the rhodopsin gene
and these are distributed along the intradiscal, transmembrane
and the cytoplasmic domains of the protein. Mutations in
rhodopsin have been classified into three different groups based
on their phenotype in heterologous cells. Class 1 mutant proteins
are expressed at levels similar to the wild type rhodopsin, form the
rhodopsin chromophore with 11-cis retinal and are transported to
the cell surface. Class-II mutants form aggregates, remain in the
endoplasmic reticulum and do not bind 11-cis retinal to form the
chromophore. Class III mutants are expressed at low levels,
remain in the endoplasmic reticulum (ER) and form rhodopsin
chromophore poorly, cause abnormal trafficking of the protein
and result in the formation of aggregates which are retained near
the endoplasmic reticulum [8,9,10]. The P23H missense mutation
is a class-III mutant and accounts for the largest fraction of cases in
the world due to rhodopsin mutations [6,7,11].
Though the genetic link between the P23H mutation in
rhodopsin (P23H-R) and RP have been well established, the
mechanism underlying photoreceptor degeneration due to this
mutation is yet to be understood. Evaluation of heterologous cells
expressing P23H-R demonstrated that the mutant rhodopsin is
prone to aggregate formation and is retained in the ER through
interactions with elements of the ER’s quality control chaperone
machinery and targeted for subsequent degradation by the
ubiquitin-proteasome pathway [12,13,14]. Aggregated mutant
rhodopsin was shown to accumulate near the centrosome, recruit
cytoskeleton proteins and form perinuclear aggresome-like struc-
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demonstrated that the mutant rhodopsin interacts with wt protein
and forms cytoplasmic inclusions [12,13,14]. Similarly, P23H-R
mutation in a Xenopus model also showed formation of aggregates
in photoreceptors [15,16,17]. Mouse and rat models with P23H-R
mutation developed photoreceptor degeneration due to defective
trafficking of rhodopsin [18,19,20]. These studies suggested that a
potential dominant negative effect exerted by P23H-R leading to
aggregation and mislocalization of rhodopsin might be the
underlying cause of photoreceptor cell death in RP [13,14].
Misfolding of proteins leading to self-aggregation and altered
protein trafficking has been implicated in other degenerative
diseases such as Alzheimer’s Disease. Inhibition of aggregate
formation and favoring the re-folding or clearance of improperly
folded proteins have been considered as potential strategies to treat
these conditions. In the past decade, a large number of synthetic
and natural compounds have been evaluated for their therapeutic
potential in treating protein trafficking defects [21]. Several
substances like molecular chaperones, growth factors, small
molecules, retinoids and anti-oxidants are known to protect cells
from the toxic events mediated by misfolded and aggregated
proteins [22,23,24,25,26,27,28]. Despite these advances, com-
pounds that are potentially effective in treating retinal degener-
ations due to protein misfolding have not been identified.
In recent times, a significant increase has been noted in the
evaluation of beneficial effects of several natural products for their
therapeutic potentials. Among these natural products, phytochem-
icals mainly polyphenols have been studied extensively with the
goal of identifying a suitable natural compound with strong
therapeutic effect and minimal toxicity. Polyphenols are derived
from many components of the human diet, including dark
chocolate, peanuts, green and black tea, red wine, olive oil, fruits,
vegetables and curry spices [29]. Some of these phytochemicals
which are the components of anti-inflammatory and wound
healing agents of traditional eastern medicine are being investi-
gated for their therapeutic potential in treating cardiovascular
diseases, inflammatory disease, diabetes, cancer etc [30,31,32,
33,34,35,36,37]. One such compound, curcumin (1,7-bis(4-
hydroxy-3- methoxyphenyl)1,6-heptadiene-3,5-dione), a principal
component of turmeric, is well known for its antitumor,
antioxidant, and anti-inflammatory properties [38,39,40,41].
Curcumin is a member of curcuminoid family and proven to
inhibit the formation of aggregates and promote the trafficking of
accumulated proteins [23,24]. The polyphenolic structure of
curcumin, (two phenol rings connected by a, b-unsaturated
carbonyl groups) allows it to cross the blood brain barrier. Anti-
protein aggregating activity of curcumin has been studied and
established in several neurodegenerative diseases [42,43,44,45].
In order to determine whether curcumin exerts anti-protein
aggregating activity in the retina and rescue photoreceptors from
degeneration due to misfolded rhodopsin, we tested the effect of
curcumin on cell lines and rats expressing the P23H rhodopsin. Our
studies demonstrated that administration of curcumin can inhibit
the formation of mutant rhodopsin protein aggregates, protect the
cells from toxic events associated with protein aggregation, improve
retinal morphology and function. These results establish the
potential therapeutic use of curcumin in treating retinal degener-
ations caused by misfolded or aggregated rhodopsin.
Results
Disruption of protein aggregates by curcumin
To assess the effect of curcumin on protein aggregation, COS-7
cells expressing wt or mutant (P23H-R) rhodopsin with V5 tag
were supplemented with 5 mM concentration of curcumin and
analyzed for the presence of protein aggregates by immunocyto-
chemistry followed by fluorescent microscopy. The concentration
of curcumin used in this study is determined on the basis of
published reports (23). These cells were co-labeled with ER maker-
PDI. Consistent with previously published data the wt rhodopsin
was found to be localized to the plasma membrane (Fig. 1A)
whereas the majority of mutant rhodopsin formed perinuclear
aggregates (Fig. 1B) [12,14]. Treating cells expressing P23H
rhodopsin with curcumin resulted in a decrease in the formation of
mutant protein aggregates. In these cells, the sub-cellular
distribution pattern of P23H rhodopsin was observed to be similar
to that of the wt protein (Fig. 1C). Mutant rhodopsin in these cells
was found to be predominantly localized to the plasma membrane.
In contrast, treatment with curcumin or vehicle had no affect on
localization pattern of wild type rhodopsin (data not shown).These
data indicate that curcumin treatment may alter the subcellular
distribution pattern of mutant rhodopsin.
Curcumin crosses blood brain and blood retina barrier
To investigate the bioavailability of curcumin in brain and
ocular tissues, 100 mg/kg body weight of curcumin was
administered to control SD rats by gavage and the amount of
compound reaching brain and various eye tissues after 2 hours of
administration was estimated by LC/MS-MS (Fig. 2A, B). The
amount of curcumin administered to rats for these studies was
reported to be in the well tolerable doses used in human clinical
studies [24,46]. Evaluation of brain tissue of curcumin adminis-
tered rats revealed the presence of 0.009 ng of curcumin/ mg
tissue weight. Analysis of different eye tissues of rats administered
with curcumin detected the presence of curcumin in sclera, retinal
pigment epithelium (RPE), retina, optic nerve, cornea, vitreous
and lens. The highest amount of curcumin (0.076–0.079 ng/mg
tissue) was observed in the Sclera+RPE and optic nerve. In the
retina and cornea the amounts of curcumin were found to be
around 0.026–0.030 ng /mg of tissue weight. Vitreous and lens
showed the presence of lowest amounts of curcumin (0.003–
0.004 ng/mg tissues weight). Presence of curcumin in the retina
and brain after 2 h of gavage indicates that orally administered
curcumin indeed crosses blood-brain and blood-retina barriers.
Curcumin improves retinal morphology
The effect of curcumin on the retinal structure of P23H-R
transgenic rats was evaluated by comparing the retinal morphol-
ogy of treated and untreated transgenic rats (Fig. 3). Consistent
with the earlier observations, untreated control P23H transgenic
rats developed severe retinal degeneration by postnatal day 60
(P60). The photoreceptor outer and inner segments at this age
were observed to be shorter and the outer nuclear layer was found
to be thin with 2–3 rows of nuclei. Whereas, transgenic rats
administered with curcumin from P30–P60 showed a significant
improvement in their retinal morphology by preserving 6 to 7 rows
of photoreceptor nuclei (Fig. 3B). The photoreceptor outer
segments of these treated rats were observed to be well preserved
compared to untreated P23H-R transgenic controls (Fig. 3A) and
the wild type control rat retina (Fig. 3C). Improved retinal
morphology observed in curcumin administered rats indicates
preservation of photoreceptors and the potential beneficial effects
of curcumin on retinal degeneration. However no significant
difference was observed in the progression of retinal degeneration
in vehicle treated rats compared to untreated control rats (data not
shown). The thickness of the outer nuclear layer (ONL) and Inner
nuclear layer (INL) in curcumin treated and vehicle treated rats
was quantified using the Aperio Image Scope software Ver.
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in the thickness of both ONL (p#3.6‘-07) and INL (p#2‘-05) of
the retina of curcumin treated P23H-R transgenic rats when
compared to vehicle treated P23H-R transgenic rats (Fig. 3D).
Levels of expression of photoreceptor marker genes is
improved upon curcumin treatment
The levels of expression of photoreceptor specific genes in the
retina of treated and untreated P23H-R transgenic rats was
studied to further evaluate the observations of morphological
analysis. Semi quantitative real-time PCR analysis of retinal tissue
from curcumin administered P23H-R transgenic rats revealed a
significant increase in the expression levels of rod photoreceptor
specific markers, rhodopsin and ROM-1) and cone photoreceptor
specific markers (S-Opsin and M-Opsin) when compared to their
levels in untreated P23H-R transgenic rats indicating preservation
of photoreceptor cells (Fig. 3E).
Curcumin improves retinal physiology
Electroretinography (ERG) was performed on curcumin
administered and untreated P23H-R transgenic rats to determine
the effect of curcumin treatment from P30 to P70 on retinal
physiology in these animals. A significant improvement in retinal
function was observed in curcumin treated rats when compared to
the untreated after 40 day treatment regimen as measured by the
a- and b-wave amplitude of the full field scotopic and the b-wave
amplitude of the photopic ERG.
The protection afforded by curcumin treatment was observed
across all measurable intensities (Fig. 4A & B). The mean
maximum scotopic a-wave amplitude in untreated rats was
28.96 mV( 69.3 mV, n=5) while rats treated with curcumin had
a mean maximum a-wave amplitude of 60.09 mV( 66.8 mV,
n=13) (p=0.012)The mean maximum scotopic b-wave amplitude
in untreated animals was 96.39 mV( 627.1 mV, n=5) while
animals treated with curcumin had a mean maximum scotopic b-
wave amplitude of 264.8 mV( 639.7 mV, n=13) (p=0. 012)
(Fig. 4D). The mean maximum photopic b-wave amplitude in
untreated rats was 32.95 mV( 64.15 mV, n=5) while rats treated
with curcumin had a mean maximum photopic b-wave amplitude
of 61.3 mV( 63.4 mV, n=13) (p=0. 002) (Fig. 4B, D). The
implicit time of the ERG amplitudes is unchanged across all
intensities between the treated and untreated groups (Fig. 4C).
This suggests that the remaining photoreceptors in the retina of
Figure 1. Dissociation of mutant protein aggregates in presence of curcumin. To test the anti-protein aggregating property of curcumin,
COS-7 cells were transfected with wt (A–C) and mutant rhodopsin (D–F); supplemented with curcumin (G–I), immunolabeled with anti-V5 (green) and
anti-PDI (red) antibodies. Mutant rhodopsin aggregates (white arrow) were dissociated upon treatment with curcumin (red arrow). In presence of
curcumin, the expression pattern of mutant rhodopsin is similar to the expression pattern of wt rhodopsin protein. Overlays of images from first two
rows on DAPI-stained nuclei of the respective cells (blue) were shown in the bottom panel. Scale bar is 5 mM.
doi:10.1371/journal.pone.0021193.g001
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untreated animals have either reduced photoreceptors or short-
ened OS. Both of which are known to be true from previous work
by Machida et al [47].
Curcumin alters the subcellular localization of P23H
rhodopsin in cells
To investigate the effect of curcumin on localization of
rhodopsin protein in the retina, cryo-sections of curcumin
administered and untreated control P23H-R transgenic rat retina
were labeled with anti-rhodopsin antibody. The rhodopsin signal
in untreated P23H-R transgenic rats was localized adjacent to the
remaining few rows of nuclei in the ONL (Fig. 5- I). In contrast,
the rhodopsin localization was observed in the outer segment
region in the retinas of curcumin administered P23H-R transgenic
rats (Fig. 5-II). The pattern of localization of rhodopsin in these
retinas is consistent with the localization observed in the retinas of
wild type rats (Fig. 5-III). These results indicate that administration
of curcumin substantially alters the localization of rhodopsin. It is
likely that curcumin facilitates the translocation of rhodopsin to
outer segment region or preserves the outer segment structure or
both.
Curcumin decreases endoplasmic reticulum (ER) stress in
cells
Previous studies reported that the P23H rhodopsin induces ER
stress and activates unfolded protein response (UPR) [14,48]. To
investigate the effect of curcumin on ER stress, the levels of
expression of two genes robustly induced by ER stress, Grp78/Bip
and CHOP, were measured in cells expressing wt and P23H
rhodopsin in presence and absence of curcumin. Quantitative real
time PCR analysis of curcumin supplemented mutant rhodopsin
expressing cells demonstrated a significant decrease in the
expression of Grp78/BiP and CHOP compared to their levels in
untreated cells (P=0.001) (Fig. 6). Supplementation of curcumin
to cells expressing wt protein did not cause significant alteration in
the level of expression of ER stress marker genes when compared
to their levels in untreated cells.
Effect of curcumin on ER stress in the retina of P23H-R
transgenic rats was also studied by comparing the expression levels
of Grp78/BiP and CHOP in the retinas of P23H-R transgenic rats
treated with curcumin from P15 to P30 and untreated controls.
Rats treated with curcumin showed higher levels of Grp78/BiP and
Chop mRNA at P20 compared to their levels at P15 and P30.
Comparison of the expression profile of these genes between the
treated and untreated groups revealed that the levels of Grp78/Bip
decreased gradually and the expression was significantly lower in
treated rats by the end of treatment on P30. Although the levels of
expression of CHOP increased significantly at P20 in curcumin
treated rats, subsequently they decreased significantly by P30.
Additional analysis is needed to determine if prolonged treatment
of curcumin will result in further reduction in the levels of CHOP
(fig. 7).
The studies on cells transfected with P23H-rhodopsin indicated
that curcumin treatment may reduce mutant rhodopsin aggrega-
tion and therefore allieviate ER stress. However, the studies on
P23H-R transgenic rats require further analysis to determine the
affect of curcumin treatment on ER stress in vivo.
Discussion
The present study investigated the therapeutic potential of
curcumin in treating retinal degenerations due to misfolded
rhodopsin. These results demonstrate that curcumin a) dissociates
the mutant protein aggregation; b) significantly improves the
retinal morphology and physiology of heterozygous P23H-R
transgenic rats; c) facilitates the translocation of mutant rhodopsin
to appropriate cellular compartment in cell culture and in vivo; and
d) decreases ER stress in transiently transfected cells expressing
P23H rhodopsin.
A wide variety of therapeutic strategies to treat retinal
degenerations are being pursued actively [26,49]. Easy access of
retinal tissue to directly deliver therapeutic material makes these
studies feasible. Gene replacement therapy by delivering missing
genes to the retina by way of injection has been shown to be
effective in treating a recessive retinal degeneration lebers
congenital amaurosis due to mutations in the RPE65 gene
[50,51]. Several other potential therapies for retinal dystrophies
are currently under development or evaluation [52,53,54,55].
Despite these advances, designing therapies for retinal degenera-
tions caused by dominant negative mutations is still a major
challenge as the strategy should include removal of the mutant
protein in addition to supplementing the missing functional
protein. Most of the gene based therapies are specific to diseases
due to mutations in particular genes or even specific only to certain
types of mutations in a gene. There are more than 200 genes
associated with retinal conditions with a large number of
mutations in some of these genes (RetNet web site-: Available:
http://www.retina-international.org, accessed 2011 June 6; Hu-
man Gene Mutation Database:- Available: http://www.hgmd.cf.
ac.uk/ac/index.php, accessed 2011 June 6). The number of
Figure 2. Bioavailability of curcumin. Amount of curcumin
detected by LC-MS/MS analysis in the eye and brain tissues of curcumin
administered SD rats. (A) Representative LC-MS/MS chromatogram of
curcumin (standard) and naringenin (internal standard). (B) Delivery of
curcumin to ocular tissues and brain of SD rats following oral
administration. Data are expressed as mean 6 SD for n=4.
doi:10.1371/journal.pone.0021193.g002
Rescue of Photoreceptor Degeneration by Curcumin
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21193patients with RD due to any specific mutation is limited.
Therefore, therapeutic strategies that are applicable to treat larger
number of patients are more effective.
Mutations leading to altered conformation of proteins have
been shown to be the underlying cause of several dominant
neurodegenerative diseases including dominant retinitis pigmen-
tosa. Protein misfolding leading to altered trafficking and
aggregation are common features of these conditions [14]. In
general, normal synthesis of proteins is followed by their folding
into three-dimensional conformation. Misfolded and unfolded ER
client proteins can lead to ER stress and increased cell death
through a number of mechanisms including, disruption of
important cellular processes such as protein trafficking and
degradation. Protein misfolding in the ER initiates natural cellular
defense known as the Unfolded Protein Response (UPR) which
leads to the up-regulation of multiple target genes, such as Grp78/
BiP and Chop. However, due to persistent accumulation of mutant
proteins, the ability of cellular defense against protein folding
decreases dramatically. In diseases like RP multiple factors
including protein misfolding, altered trafficking, induction of ER
Figure 3. Improved retinal morphology and gene expression of P23H transgenic rats upon administration of curcumin. Light
micrographs of retinal sections from untreated control (A) and curcumin treated (B) and wild type Wistar rat retina (C) P23H-R transgenic rats
demonstrated a significant improvement in retinal morphology in curcumin administered rats compared to untreated controls. OS=outer segments;
IS=inner segments; ONL=outer nuclear layer; OPL=outer plexiform layer and INL=inner nuclear layer; IPL=inner plexiform layer; GC: Ganglion cell
layer. The thickness of the ONL and INL in curcumin treated rats were quantified using Aperio Image Scope software Ver. 10.2.2.2319 program (D). We
found significant increase in the thickness of both ONL (p#3.6‘-07) and INL (p#2‘-05) of the retina of curcumin treated P23H rats when compared to
vehicle treated P23H rats. The results are presented as Mean6 SD with ** denoting p-values,0.005. Quantitative expression of rod photoreceptor
specific markers Rho and Rom-1 and cone specific makers S-Opsin and M-Opsin(E) demonstrated an increased expression in curcumin treated rat
retinas (Gray bars) is compared to untreated controls (white bars). Gene expression data is calculated from at least 3 independent samples, each of
which was analyzed at least in 3 replication reactions. The results are presented as Mean6 SD with ** denoting p-values,0.005.
doi:10.1371/journal.pone.0021193.g003
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treated with curcumin at 100 mg/kg body weight dose (n=13. Solid lines/bars in all panels). (A) The treated animals have improved
scotopic A and B-wave amplitudes and improved (B) photopic B-wave amplitudes across all intensities compared to untreated rats. (C) The amplitude
latencies remain unchanged in untreated rats suggesting no appreciable change in photoreceptor function. While A and B-wave amplitudes are
clearly improved in the treated animals, a statistically significant (students t-test p,0.05) difference is observed in the maximum scotopic and
photopic B-wave amplitudes of treated rats when compared to untreated P23H-R transgenic controls (D).
doi:10.1371/journal.pone.0021193.g004
Figure 5. Translocation of Rhodopsin to photoreceptor outer segments in presence of curcumin. Immunohistochemical analysis of
retinal sections of curcumin treated P23H-line-1 transgenic rats with rhodopsin demonstrated the translocation of Rhodopsin protein to
photoreceptor outer segment region. In control untreated retinal sections rhodopsin was found to be accumulated near the inner segment region of
photoreceptors. Red indicates the labeling of rhodopsin in panels I and II and green indicates the rhodopsin labeling in panel III. Nuclei are stained
with DAPI. Scale bar is 5 mM. The localization of rhodopsin is observed away from the nuclei in curcumin treated rats contrary to the localization of
rhodopsin observed adjacent to the nuclei in untreated control rats thus suggesting the translocation of rhodopsin to outer segments.
doi:10.1371/journal.pone.0021193.g005
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the pathogenesis. These interlinked pathways are predicted to
have multiple potential sites for therapeutic intervention. There-
fore identification of suitable pharmacological agents targeting the
mutant protein, activation of chaperones which in turn facilitate
protein folding and enhance the translocation of proteins from ER
is beneficial.
Small molecules like curcumin which are known to have
multiple therapeutic properties could be effective in treating
diseases caused by protein aggregation. Curcumin has been widely
used as a coloring agent in food as well as a traditional Indian
‘‘Ayurvedic’’ medicine. Because of its use as a food additive,
potential for cancer chemoprevention and decrease in amyloid
plaque formation curcumin has undergone toxicological screening
and pre-clinical investigation in various disease models and found
to be safe [46,56,57]. In addition, curcumin is also reported to
reduce oxidative damage and amyloid pathology [43,58].
Recently, direct interaction of curcumin with amyloid b (Ab), a-
synuclein and transthyretin and inhibition of their aggregation has
been demonstrated [59]. Until now the exact mechanism of action
of curcumin in treating degenerative diseases or various cancers is
not understood completely. Several studies demonstrated that
curcumin exerts its anti-oxidant and anti-carcinogenic activity by
altering the activity of NF-kB, AKT/mTOR, AP-1, NRF2, and
protein kinases [60]. Curcumin was also reported to be a more
potent free radical scavenger than other antioxidants like vitamin
E [61]. Since many pathological states of the degenerative diseases
especially neurodegenerations including retinal degeneration
involve aggregation of proteins, oxidative stress, and chronic
inflammatory response, curcumin has been considered a promis-
ing compound to treat degenerative diseases caused by such
factors. Recent reports demonstrated beneficiary effects of
curcumin against a light induced damage model, chronic anterior
uvetis, and cataract formation [62,63,64,65,66]. These studies also
indicated that curcumin exerts its protective effect by modifying
the activity of NF-kB, AKT, AP-1, NRF2.
Dissociation of P23H-R aggregates, improvement of retinal
morphology and physiology observed upon curcumin treatment in
our studies in addition to its reported antioxidant, anti-inflamma-
tory and anti-amyloid plaque formation properties support the
potential of curcumin as a therapeutic agent to treat degenerative
diseases caused by mutated and misfolded proteins. Although the
precise mechanism underlying the photoreceptor rescue in P23H-
R transgenic rats by curcumin is unclear, the results of our studies
suggest that curcumin may exert its effects through modulation of
ER stress and UPR pathways. These observations further suggest
that treatment with curcumin may relieve the toxic events
associated with mutant rhodopsin protein aggregates. These
studies also indicate that modulation of ER stress is likely, but
one of several mechanisms by which curcumin enhances
photoreceptor cell survival. Since photoreceptor degeneration in
RP is associated with induction of UPR and protein aggregation,
minimizing or dissociating protein aggregates and thereby
reducing ER stress may be of great therapeutic benefit in
prolonging the survival of photoreceptors. Further studies are
required to understand the exact molecular mechanism underlying
the anti-aggregation properties of curcumin.
The evidence provided in this study indicates the therapeutic
potential of curcumin in treating RP due to P23H-R mutation.
Although the 100 mg/kg body weight dose of curcumin used in
study was reported to be clinically safe, additional careful
evaluation is needed to establish the duration of preservation of
photoreceptors upon treatment with curcumin, length of preser-
vation after termination of the treatment, minimal effective dose
and toxicity. Curcumin is likely to be effective in delaying the
onset, slow the progression of RP due to P23H rhodopsin
mutation and other degenerations due to protein trafficking
defects. Administration of curcumin in combination with other
therapies such as gene replacement therapy may be more effective
in treating diseases due to dominant negative mutations.
Methods
Reagents and antibodies used in this study: Mouse monoclonal
anti-rhodopsin antibody (1 in 1000 dilution- chemicon, Temecu-
la,CA), anti-mouse Alexa fluor 555 (1 in 5000 dilution, Invitrogen,
Carlsbad, CA), Rabbit anti-PDI antibody (1 in 200 dilution,
Abcam, Cambridge, MA). Anti-V5 antibody (Invitrogen, Carls-
bad, CA), Anti-Rabbit Alexa fluor 488 (1 in 1000 dilution,
Invitrogen, Carlsbad, CA), curcumin (Sigma- Aldrich, St.Louis,
MO, USA). Super Script
TM First-Strand Synthesis System
(Invitrogen, Carlsbad, CA, USA).
DNA construct and site directed mutagenesis
The pcDNA 3.1 n V5 DEST rhodopsin (Wt) construct was
generated by Gateway cloning strategy (Invitrogen corp, Carlsbad,
CA). As per the manufacturer’s instructions the pENTER-
directional-TOPO entry clones were created by PCR amplifica-
tion of the cDNA sequence corresponding to the entire coding
region of human rhodopsin. These entry clones were used for
recombination reaction in the Gateway pcDNA 3.1 nV5 DEST
vector carrying the V5 tag. The P23H-rhodopsin construct was
prepared by using the PCR- mediated site directed mutagenesis kit
(Invitrogen corp, Carlsbad, CA). By PCR amplification and direct
sequencing of the entire clone, all the above constructs were
confirmed to be in-frame cloning with the fusion tag.
Animal Maintenance
Homozygous P23H rhodopsin-line-1 transgenic rats were
provided by Dr. Matthew LaVail (University of California at
Figure 6. Decreased expression of ER stress markers in
curcumin treated COS-7 cells expressing mutant rhodopsin.
Quantitative expression of ER stress responsive genes Grp78/Bip and
Chop were determined by qRT-PCR. Expression values were presented
on an arbitrary scale (y-axis) after normalization with the house keeping
gene RPL-19. Data represent the mean (6SD) on an arbitrary scale and
were calculated from at least three independent observations. P,0.001
(**), and P,0.025(*).
doi:10.1371/journal.pone.0021193.g006
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study are heterozygous P23H-line-1 transgenic rats, produced by
breeding P23H-line-1 homozygous rats with age matched control
Sprague Dawley rats (SD). These studies were conducted in
accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research, and with approval of the
Committee on the Use and Care of Animals of the University of
California San Diego.
Preparation of curcumin
To test the in vitro effect of curcumin, stocks were prepared by
dissolving curcumin in DMSO. To study the effect of curcumin on
P23H aggregate formation, 5 mM concentration of curcumin was
added to cells along with the transfection complex and incubated
at 37uC. After 48 h of transfection, cells were washed and
processed for immunolabeling. For administrating curcumin to
P23H line-1 transgenic rats, curcumin was dissolved in alimentum
(hypoallergic milk powder). To study the effect of curcumin on the
morphology and physiology of P23H line 1 transgenic rat retina,
100 mg/ kg body weight of curcumin dissolved in alimentum was
administered everyday by oral gavage from P30-till P70 days. For
evaluation of gene expression, curcumin was administered from
postnatal day 7 (P7) to P30.
Cell culture and Immunofluorescence analysis of
transfected COS-7 cells
Culturing of COS-7 cells and Immunofluorescence analysis of
post transfected cells was carried out as described earlier [67,68].
Immunofluorescence was visualized with a Zeiss laser scanning
confocal microscope. Images were captured using appropriate
filters and lasers.
Quantitative real time PCR
Isolation of total RNA from COS-7 cells transfected with rho
constructs, curcumin administered and untreated control rat
retina, cDNA synthesis and quantitative real-time PCR were
performed as described previously[68,69]. Comparative Ct
method was used to calculate the expression levels of ER specific
markers as described earlier [48,70,71].
Figure 7. Modulation of ER stress response in curcumin treated P23H-R retina. Expression of ER stress response genes (A) Grp78/BiP and (B)
CHOP in the retina of P23H-R transgenic rats treated daily with (100 mg/kg body weight) curcumin from postnatal day seven (P7) to P15 or P20 or P30
and age matched untreated controls . Expression values are presented on an arbitrary scale after normalization with the house keeping gene RPL-19.
Data represents the mean (6 SD) expression levels in curcumin treated animals (white) relative to untreated controls (black) at each time point with
** denoting p-values,0.01.
doi:10.1371/journal.pone.0021193.g007
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Bioavailability studies were carried out in control Sprague
Dawley (SD) rats by administering 100 mg/ kg body weight
curcumin orally. Animals were sacrificed after 2 h of administra-
tion; brain and eyes were collected and snap frozen. Eyes were
dissected in frozen condition to isolate the various ocular tissues.
Curcumin was extracted from rat eye and brain tissues by
acetonitrile protein precipitation method using naringenin as an
internal standard. The calibration curves for analysis of curcumin
was prepared only in rat brain tissue in the concentration range of
1–500 ng/ml using 100 ng/ml naringenin as internal standard.
Sample analysis was carried out using an API-3000 triple
quadruple mass spectrometry (Applied Biosystems, Foster City,
CA, USA) coupled with a PerkinElmer series-200 liquid
chromatography (Perkin Elmer, Walthm, Massachusetts, USA).
Analytes were separated on Kromasil C18 column (2.1650 mm,
5 mm) using 5 mM ammonium formate in water pH 4.0 (A) and
acetonitrile (B) as mobile phase (30:70 (A:B) v/v) with flow rate of
0.25 ml /min and total run time of 3 min. Curcumin and
naringenin (internal standard) were analyzed in negative ioniza-
tion mode with following multiple reaction monitoring (MRM)
transitions: 367R271 (curcumin); 271R151 (naringenin).
Histological evaluation
For evaluation of retinal histology, eyes from 5 curcumin
administered P23H-line-1 animals and control animals were
collected and processed for histology as reported earlier [71,72].
Tissue sections were stained with H&E and viewed under Nikon
light microscope.
Electroretinograms
Electroretinograms (ERG) were recorded from one eye of the
anesthetized P23H line-1 transgenic rat to determine retinal
function. Twenty-four hours prior to recording ERG, animals
were weighed and allowed to dark adapt overnight (food and
water are available ad libitum). All subsequent procedures were
performed in the dark with a dark-room safelight or night vision
goggles as reported previously [47].
Immunohistochemistry
For evaluation of localization of rhodopsin in curcumin
administered P23H-line-1 transgenic and age matched control
rat retina, immunohistochemistry was performed using anti-
rhodopsin antibody as described earlier [72,73].
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